116 related articles for article (PubMed ID: 11077962)
1. Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker.
Majali MA; Mathakar AR; Shimpi HH; Banerjee S; Samuel G
Appl Radiat Isot; 2000 Dec; 53(6):987-91. PubMed ID: 11077962
[TBL] [Abstract][Full Text] [Related]
2. Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.
Deilami-Nezhad L; Moghaddam-Banaem L; Sadeghi M
Appl Radiat Isot; 2017 Nov; 129():108-116. PubMed ID: 28843158
[TBL] [Abstract][Full Text] [Related]
3. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
4. Preliminary dosimetry of (166)Ho-propylene di-amino tetra (methy1enephosphonicacid) for human based on biodistribution data in rats.
Zolghadri S; Yousefnia H; Jalilian AR; Shiri-Yekta Z; Maragheh MG
J Cancer Res Ther; 2015; 11(4):862-7. PubMed ID: 26881532
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model.
Louw WK; Dormehl IC; van Rensburg AJ; Hugo N; Alberts AS; Forsyth OE; Beverley G; Sweetlove MA; Marais J; Lötter MG; van Aswegen A
Nucl Med Biol; 1996 Nov; 23(8):935-40. PubMed ID: 9004281
[TBL] [Abstract][Full Text] [Related]
6. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
7. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
[TBL] [Abstract][Full Text] [Related]
8. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals.
Garnuszek P; Pawlak D; Licińska I; Kamińska A
Appl Radiat Isot; 2003 Apr; 58(4):481-8. PubMed ID: 12672628
[TBL] [Abstract][Full Text] [Related]
10. Optimized Production and Biological Evaluation of
Tadayon N; Yousefnia H; Ramazani A; Zolghadri S; Alirezapour B; Jalilian AR; Afarideh H; Vaez-Tehrani M
J Med Imaging Radiat Sci; 2019 Mar; 50(1):142-148. PubMed ID: 30777236
[TBL] [Abstract][Full Text] [Related]
11. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation.
Chakraborty S; Das T; Banerjee S; Chaudhari PR; Sarma HD; Venkatesh M; Pillai MR
Nucl Med Commun; 2004 Dec; 25(12):1169-76. PubMed ID: 15640774
[TBL] [Abstract][Full Text] [Related]
12. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
13. High-dose treatment with (186)Re-HEDP or (153)Sm-EDTMP combined with amifostine in a rabbit model.
Brenner W; Kampen WU; von Forstner C; Brümmer C; Zuhayra M; Muhle C; Czech N; Henze E
J Nucl Med; 2001 Oct; 42(10):1545-50. PubMed ID: 11585871
[TBL] [Abstract][Full Text] [Related]
14. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
15. Uptake of ethylenediamine tetramethylene phosphonic acid in normal bone after multiple applications. A non-human primate study.
Dormehl IC; Louw WK; Schneeweiss FH; Milner R; Schmitt G; Carl U; Croft SA
Arzneimittelforschung; 1998 Apr; 48(4):408-14. PubMed ID: 9608885
[TBL] [Abstract][Full Text] [Related]
16. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
17. Formulation of 99mTc-Sn-EDTMP: freeze-dried kit for bone scanning.
Mushtaq A
Nucl Med Biol; 1998 Apr; 25(3):313-5. PubMed ID: 9620638
[No Abstract] [Full Text] [Related]
18. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of samarium-153-EDTMP in rats treated with docetaxel.
Villarim Neto A; Açucena MK; Pereira KR; Rêgo AC; Azevedo IM; Bernardo-Filho M; Medeiros AC
Acta Cir Bras; 2009; 24(1):62-6. PubMed ID: 19169545
[TBL] [Abstract][Full Text] [Related]
20. Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping.
Han YJ; Loo SC; Phung NT; Ong HT; Russell SJ; Peng KW; Boey F; Ma J
J Mater Sci Mater Med; 2008 Sep; 19(9):2993-3003. PubMed ID: 18360794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
